Alto Neuroscience, Inc. /
Chase Therapeutics Corporation
Alto Neuroscience purchases drug combination assets from Chase Therapeutics Corporation
What happened
Alto Neuroscience, Inc. entered into an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations, including ALTO-207 for treatment resistant depression.
Alto paid $1,750,000 upfront, and Chase Therapeutics Corporation is eligible for up to $71.5 million in future milestone payments.
The source
Everything on this page comes from the source below.
Alto Neuroscience purchases drug combination assets from Chase Therapeutics Corporation
This document is the source for the companies, stage, figure and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly